The agency approves annual vaccination for adults 75 and older and immunocompromised.
The Centers for Disease Control (CDC) recommended the annual use of vaccines for respiratory syncytial virus (RSV) for adults over the age of 75 and high-risk adults between the ages of 60 and 74. This updated the agency’s 2023 position, which included younger adults in its recommendation, and is expected to decrease the annual administration of RSV vaccines from 93 million to approximately 55 million.
“The CDC has updated its RSV vaccination recommendation for older adults to prioritize those at highest risk for serious illness from RSV,” CDC Director Mandy Cohen stated.
Because healthy people experience RSV symptoms which resemble a common cold, the illness may be undetected. For younger children and older adults, RSV may cause more severe illnesses, such as bronchitis or pneumonia, that may result in hospitalization.
As the Lord Leads, Pray with Us…
- For discernment for Director Cohen and CDC officials as they consider recommendations for vaccinations.
- For U.S. federal health officials to be prudent in their advisories and policies.
Sources: Reuters, Centers for Disease Control and Prevention
